| 產(chǎn)品描述： | PLpro inhibitor is a potent inhibitor of papain-like protease (PLpro) with an IC50 of 2.6 μM. PLpro inhibitor inhibits SARS-CoV-2 PLpro with an IC50 of 5.0 μM and an EC50 of 21.0 μM |
| 靶點(diǎn)： |
IC50 : 2.6 μM (Papain-like protease (PLpro)); 5.0 μM (SARS-CoV-2 PLpro) EC50: 21.0 μM (SARS-CoV-2 PLpro);SARS-CoV |
| 體外研究： |
PLpro inhibitor is a potent inhibitor against the papain-like protease (PLpro) from the coronavirus that causes severe acute respiratory syndrome (SARS-CoV). PLpro inhibitor was found to have IC50 value of 2.6 μM. PLpro inhibitor display significant antiviral activity with EC50 values of 13.1 μM, without toxicity up to the highest concentration tested. Notably, the increasing antiviral potency correlates with the in vitro inhibition of PLpro, suggesting that the compounds work directly on the enzyme in cells |
| 參考文獻(xiàn)： |
1. Ratia, K., et al., A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A, 2008. 105(42): p. 16119-24. 2. http://www.google.com/patents/WO2010022355A1cl=en 3. Brendan T Freitas, et al. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease. ACS Infect Dis. 2020 May 19. |
| 溶解性： |
soluble in DMSO |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.887 ml |
14.433 ml |
28.867 ml |
| 5 mM |
0.577 ml |
2.887 ml |
5.773 ml |
| 10 mM |
0.289 ml |
1.443 ml |
2.887 ml |
| 50 mM |
0.058 ml |
0.289 ml |
0.577 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶(hù)參考交流研究之用。 |
上海工商
危險(xiǎn)品化學(xué)品經(jīng)營(yíng)許可證（不帶存儲(chǔ)）
營(yíng)業(yè)執(zhí)照(三證合一)
北京